Oct 24, 2018
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
Apr 27, 2018
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 10, 2018
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Dec 21, 2017
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Nov 28, 2017
Global Benign Prostatic Hyperplasia Market and Competitive Landscape 2017-2025
Nov 01, 2017
AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
Oct 30, 2017
CMP Pharma, Inc Announces That CaroSpir®, The First And Only FDA-Approved Spironolactone Oral Suspension, Is Now Available
Oct 19, 2017
Badger Licensing to Provide Technology for New Bisphenol A Plant in China
Oct 18, 2017
Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells
Oct 11, 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Oct 03, 2017
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)
Sep 14, 2017
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Sep 14, 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Sep 07, 2017
TOLMAR Pharmaceuticals Champions Prostate Cancer Awareness Month
Sep 06, 2017
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Aug 31, 2017
Astellas to Present New Data for Enzalutamide and IMAB362 at 2017 European Society of Medical Oncology (ESMO) Annual Meeting
Aug 07, 2017
CMP Pharma, Inc. Announces FDA Approval of CaroSpir® (Spironolactone Oral Suspension, 25 mg/5 mL)
Jun 13, 2017
Prostate Cancer Therapeutics Market Size Worth $12.0 Billion by 2025: Grand View Research, Inc.
Jun 09, 2017
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Jun 03, 2017
Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival